First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
Journal of Thoracic Oncology(2018)
摘要
AC0010 had a well-tolerated safety profile, and promising antitumor activity in NSCLC patients with acquired resistance to first generation EGFR-TKI, supporting its continued development.
更多查看译文
关键词
EGFR,T790M,cell-free DNA,next-generation sequencing
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络